Investors & Media Value through vision

Photo of a scientist working in a laboratory

Located in Leiden, Netherlands and Cambridge, Mass., ProQR Therapeutics (Nasdaq:PRQR) is a clinical-stage biotechnology company developing RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited blindness.

Our platform based on intravitreal delivery uses chemically modified single-stranded RNA oligonucleotides to repair defective RNA. Given the high unmet need across more than 300 inherited retinal diseases, our RNA therapies have broad potential to change lives by stopping or reversing vision loss. We are evaluating sepofarsen in a pivotal Phase 2/3 trial for LCA10, QR-421a in a Phase 1/2 trial for RP and Usher syndrome, and QR-1123 for RP, along with advancing earlier stage assets.

Events

A list of past and future conferences and events

Where to meet us

events icon

Financial information

Latest SEC filings, annual reports and AGM documents

View details

Financial information icon

Presentations and publications

The latest scientific publications for our development programs

View scientific publications

presentations and publications icon

Corporate governance

Documents related to corporate governance

Go to documents

corporate governance icon

Analysts

A list of the analysts that cover ProQR

See the list

analysts icon

ProQR Share Performance